SHANGHAI, Dec. 31, 2024 — CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a developer of innovative CAR T-cell therapies for blood cancers and solid tumors, reports the launch of an investigator-initiated trial (IIT) in China for KJ-C2219. This allogeneic CAR T-cell therapy targets CD19/CD20 and will be assessed in treating relapsed/refractory B-cell non-Hodgkin lymphoma (R/R B-NHL).
KJ-C2219 is built upon CARsgen’s THANK-u Plus platform, designed for blood cancers and autoimmune disorders.
About THANK-u Plus
CARsgen’s THANK-u Plus platform enhances its proprietary THANK-uCAR® allogeneic CAR-T technology, mitigating potential NKG2A expression effects on treatment success. THANK-u Plus ensures consistent expansion irrespective of NKG2A levels on NK cells, showing substantially improved expansion over THANK-uCAR®. Preclinical data indicate superior antitumor activity with THANK-u Plus in the presence of NK cells compared to THANK-uCAR®. Allogeneic BCMA or dual-targeting CD19/CD20 CAR-T cells using this platform demonstrate strong antitumor action with NK cells, suggesting broad potential for diverse allogeneic CAR-T therapies.
About CARsgen Therapeutics Holdings Limited
CARsgen, a biopharmaceutical company operating in China and the U.S., focuses on innovative CAR T-cell therapies for blood cancers and solid tumors. CARsgen possesses a comprehensive CAR T-cell R&D platform encompassing target identification, novel CAR T-cell development, clinical trials, and commercial production. CARsgen has developed novel technologies and a product pipeline with global rights, addressing key challenges in existing CAR T-cell therapies, including safety, solid tumor efficacy, and cost reduction. CARsgen aims to be a global leader in providing innovative cell therapies for cancer patients worldwide, striving to make cancer curable.
Forward-looking Statements
Statements in this release that are not historical facts are forward-looking statements. These statements reflect the Group’s current views, projections, and expectations regarding future events. Such statements are based on assumptions and factors beyond the Group’s control and are subject to significant risks and uncertainties. Actual events may differ materially. These risks and uncertainties are detailed in the “Principal Risks and Uncertainties” section of our most recent annual and interim reports and other announcements on our website. No assurance is given regarding the achievement or reasonableness of any projections, targets, estimates, or forecasts in this release.
For more information, please visit
SOURCE CARsgen Therapeutics